Regulatory information is provided for editorial and research purposes and should be verified directly with the relevant authority.
On 30 October 2023 the World Health Organization assessed the Saudi Food and Drug Authority at Maturity Level 4 for medicines and vaccines, the highest level in its classification, making the SFDA the third regulatory authority worldwide and the first in the Eastern Mediterranean to reach it. That assessment is the mechanism behind almost every subsequent observation about Saudi approvals carrying weight elsewhere.
Two details give it its precise meaning. It applies to medicines and vaccines, the scope of the WHO assessment, with medical devices regulated on their own track. And it is a benchmarking outcome about the regulator's systems, rather than a guarantee about any individual decision.
The UAE consolidated, then devolved again
Federal Decree-Law No. 38 of 2024 created the Emirates Drug Establishment, which assumed product registration from the Ministry of Health and Prevention. A single federal certificate now covers the country. Facility licensing, formulary inclusion and procurement remain emirate-level decisions taken by the Department of Health Abu Dhabi and the Dubai Health Authority.
Separating federal registration from emirate-level licensing is the key to reading the UAE correctly, because the two processes have different authorities, different timelines and different evidence requirements.
How the other four work
Qatar concentrates authority in the Ministry of Public Health and generally requires prior authorisation from a founding GHTF jurisdiction before its own technical review proceeds. Bahrain's National Health Regulatory Authority requires registered authorised representatives and recognises reference-market approvals. Kuwait regulates devices through the Ministry of Health under Ministerial Decree No. 13 of 2022. Oman operates a device portal and has set an import compliance deadline.
Published review timelines are the next transparency milestone for all four. A7i carries regulatory deadlines once they are traced to the issuing authority, and the corrections log lists the dates held for confirmation on that basis.
The Oman date, as sourced
The sourced deadline for Omani device registration is six months from 22 April 2026, after which shipments from non-compliant firms are suspended at entry points. It replaces a 1 July 2026 date previously carried on this site. A7i carries the sourced version and records the change openly in the corrections log.
What the centralised route covers
The Gulf Health Council operates a centralised registration procedure that produces a joint scientific assessment for pharmaceuticals. Medical devices and in-vitro diagnostics are regulated nationally in all six states, and national registration and national certificates in each member state complete the process alongside the joint assessment.
Speed as a regulatory position
Gulf regulators have cleared several frontier therapies at or before Western markets: an ESR1-targeted breast cancer therapy approved in the UAE in June 2026 shortly after Saudi clearance and ahead of a United States advisory committee recommendation, and a once-daily oral GLP-1 registered in the UAE in April 2026 as reportedly the second market worldwide.
Whether this reflects independent analytical capacity or efficient reliance on reference dossiers is a question the public record leaves open. What is observable is that the sequence in which frontier medicines reach markets has changed, and that the Gulf now appears near the front of it.